Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 3/2012

01-03-2012 | Original Article

Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice

Authors: Chunyan He, Xuehong Lu, Zhaowei Yan, Man Wu, Shujun Liu, Yongli Yu, Ping Luo

Published in: Rheumatology International | Issue 3/2012

Login to get access

Abstract

Mice with chronic graft-versus-host disease (cGVHD) induced by transferring parental BALB/C lymphocytes into (C57BL/6 × BALB/C) F1 (CBF1) hybrids, develop a syndrome characterized by B-cell hyperactivity, autoantibody production, and immune complex-mediated glomerulonephritis. In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity. Daily administration of leflunomide (15 mg/kg/d) from 2 weeks after cGVHD induction can dramatically reduce the production of autoantibodies and immune complex deposition in the kidney, leading to relieved kidney damage and reduced mortality. The therapeutic effect of leflunomide on the lupus-prone mice was partially due to the inhibition of TLR9 signaling pathway, which was an important component of innate immune system.
Literature
1.
Aurelia L, Philippe C, Isabelle A et al (2006) Role of TLR9 in anti-nucleosome and Anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol 177:1349–1354
2.
Nagy G, Koncz A, Perl A (2005) T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25(2):123–140PubMedCrossRef
3.
Hahn BH, Ebling F, Singh RR et al (2005) Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 1051:433–441PubMedCrossRef
4.
Christensen SR, Kashgarian M, Alexopoulou L et al (2005) Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 202:321–331PubMedCrossRef
5.
Nakano S, Morimoto S, Suzuki J et al (2008) Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 47:145–149PubMedCrossRef
6.
Laan RF, van Riel PL, van de Putte LB (2001) Leflunomide and methotrexate. Curr Opin Rheumatol 13(3):159–163PubMedCrossRef
7.
Vidic-Dankovic B, Kosec D, Damjanovic M et al (1995) Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 17:273–281PubMedCrossRef
8.
Bartlett RR, Anagnostopulos H, Zielinski T et al (1993) Effects of leflumomide on immune responses and models of inflammation. Springer Semin Immunopathol 14:381–394PubMedCrossRef
9.
Thomas K, Klaus T, Hans-Peter H, Stefan J (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124:1791–1802CrossRef
10.
Wang HY, Cui TG, Hou FF et al (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17(7):638–644PubMedCrossRef
11.
Zhang FS, Nie YK, Jin XM et al (2009) The efficacy and safety of lefunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int 29(11):1331–1335PubMedCrossRef
12.
Tam LS, Li EK, Wong CK et al (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13(8):601–604PubMedCrossRef
13.
Wernick RM, Smith DL, Houghton DC et al (1993) Reliability of histologic scoring for lupus nephritis: a community-based evaluation. Ann Intern Med 119:805–811PubMed
14.
Trouw LA, Seelen MA, Duijs JM et al (2003) Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 132:32–39PubMedCrossRef
15.
Van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ et al (1994) A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174:311–320PubMedCrossRef
16.
Popovich S, Bartletr RR (1987) The use of the murine chronic graft versus host (CGVH) disease, a model for systemic lupus erythematosus (SLE) for drug discovery. Agents Actions 21:284CrossRef
17.
Bruijn JA, Van Elven EH, Hogendorn PCW et al (1988) Murine chronic graft versus host disease as a model for lupus nephritis. Am J Pathol 130:639PubMed
18.
Rolink AG, Radaszkiewicz T, Melchers F (1987) The autoantigen binding B cell repertoires of normal and of chronically graft versus host diseased mice. J Exp Med 165:1675PubMedCrossRef
19.
Vidic-Dankovic B, Kosec D, Damjanovic M et al (1995) Leflunomide prevents thedevelopment of experimentally induced myasthenia gravis. Int J Immunopharmacol 17(4):273–281PubMedCrossRef
20.
Means TK, Latz E, Hayashi F et al (2005) Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115:407–417PubMed
21.
Rifkin IR, Leadbetter EA, Busconi L et al (2005) Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 205:27–42CrossRef
22.
Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15:854–867PubMedCrossRef
23.
Imai H, Hamai K, Komatsuda A et al (1997) IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 51:270–276PubMedCrossRef
24.
Grootscholten C, van Bruggen MC, van der Pijl JW et al (2003) Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 48:1355–1362PubMedCrossRef
25.
Bootsma H, Spronk PE, Ter Borg EJ et al (1997) The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus: a prospective long-term observation. Ann Rheum Dis 56:661–666PubMedCrossRef
26.
Clough JD, Valenzuela R (1980) Relationship of renal histopathology in SLE nephritis to immunoglobulin class of anti-DNA. Am J Med 68:80–85PubMedCrossRef
27.
Taki S, Hirose S, Kinoshita K et al (1992) Somatically mutated IgG anti-DNA antibody clonally related to germ-line encoded IgM anti-DNA antibody. Eur J Immunol 22:987–992PubMedCrossRef
28.
Pisetsky DS, Jelinek DF, McAnally LM et al (1990) In vitro autoantibody production by normal adult and cord blood B cells. J Clin Invest 85:899–903PubMedCrossRef
29.
Witte T, Hartung K, Sachse C et al (1998) IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. Rheumatol Int 18:85–91PubMedCrossRef
30.
Forger F, Matthias T, Oppermann M et al (2004) Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 13:36–44PubMedCrossRef
Metadata
Title
Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice
Authors
Chunyan He
Xuehong Lu
Zhaowei Yan
Man Wu
Shujun Liu
Yongli Yu
Ping Luo
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1630-z

Other articles of this Issue 3/2012

Rheumatology International 3/2012 Go to the issue

Letter to the Editors

A spontaneous intercostal artery hemorrhage in systemic lupus erythematosus

Review

The association of Raynaud’s syndrome with carpal tunnel syndrome: a meta-analysis

Original Article

Three unusual mimics of primary angiitis of the central nervous system

Review

Bone marrow lesions: a universal bone response to injury?

Original Article

The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China

Original Article

A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits